Chronic myeloid leukemia (CML) stem cells appear resistant to tyrosine kinase inhibitors (TKIs) in vitro, but their impact and drug sensitivity in vivo has not been systematically assessed. We prospectively analyzed the proportion of Philadelphia chromosomepositive leukemic stem cells (LSCs, Ph þ CD34 þ CD38 À ) and progenitor cells (LPCs, Ph þ CD34 þ CD38 þ ) from 46 newly diagnosed CML patients both at the diagnosis and during imatinib or dasatinib therapy (ClinicalTrials.gov NCT00852566). At diagnosis, the proportion of LSCs varied markedly (1-100%) between individual patients with a significantly lower median value as compared with LPCs (79% vs 96%, respectively, P ¼ 0.0001). The LSC burden correlated with leukocyte count, spleen size, hemoglobin and blast percentage. A low initial LSC percentage was associated with less therapy-related hematological toxicity and superior cytogenetic and molecular responses. After initiation of TKI therapy, the LPCs and LSCs rapidly decreased in both therapy groups, but at 3 months time point the median LPC level was significantly lower in dasatinib group compared with imatinib patients (0.05% vs 0.68%, P ¼ 0.032). These data detail for the first time the prognostic significance of the LSC burden at diagnosis and show that in contrast to in vitro data, TKI therapy rapidly eradicates the majority of LSCs in patients.
INTRODUCTION
Targeted therapy with tyrosine kinase inhibitors (TKIs) (imatinib, dasatinib, nilotinib) efficiently induces rapid hematological and cytogenetic remission in most chronic myeloid leukemia (CML) patients. [1] [2] [3] [4] [5] [6] [7] [8] However, in vitro experiments have suggested that CML stem cells are resistant to TKIs. [9] [10] [11] [12] This could be due to different survival mechanisms operating in CML stem cells, which are BCR-ABL1 kinase independent. [13] [14] [15] Remaining primitive leukemia stem cells (LSCs) have also been found in the bone marrow (BM) samples of CML patients even after years on therapy, but usually these patients have had measurable disease left also in the mononuclear cell fraction. [16] [17] [18] The residual LSC population may serve as a reservoir for development of drug-resistant clones, as it has been shown that CML progenitors have chromosomal instability 19 and that most often drug resistance arises as a result of kinase domain mutations in the stem or progenitor cell compartment. 20, 21 Although the phenotype of CML stem cells is not well characterized, it is likely that the most primitive LSCs reside amongst the CD38-negative fraction of CD34-positive hematopoietic stem cells. 11, 22, 23 The effects of TKI therapy on different fractions of stem cells in vivo are largely unknown. In vitro data on human primary cells have indicated that dasatinib targets an earlier stem cell population than imatinib. 10 In vivo, this may translate into better long-term disease control, lower rate of drug resistance and, theoretically, to the cure of a proportion of patients.
To test this hypothesis, a phase II pilot study was initiated in which we enumerated the malignant and non-malignant stem cell pool in BM with flow cytometry and fluorescence in situ hybridization (FISH) and compared the effects of 2 TKIs, imatinib and dasatinib. We hypothesized that initial leukemia burden at the early progenitor and stem cell level could predict therapeutic response. Furthermore, the kinetics of drug response at the progenitor and stem cell level might serve as an important surrogate marker for long-term response and may predict likelihood of early relapse.
MATERIALS AND METHODS Patients
Patients were eligible for the study if they were 18 years of age or older, had been diagnosed with chronic phase CML within the past 3 months and had not been treated with any TKI before study entry. In addition, an adequate BM aspiration sample before the start of study treatment was a prerequisite (that is, number of aspirated cells was sufficient for stem cell analysis).
The study was performed in accordance with the Declaration of Helsinki. All patients provided a written informed consent. The study was approved by the local institutional review boards in all centers and by the national medicinal authorities in Finland, Norway and Sweden. This study was registered at ClinicalTrials.gov (number NCT00852566) before the inclusion of the first patient. Imatinib was prescribed from usual sources in each country, but dasatinib was provided as study drug by Bristol-Myers Squibb (Princeton, NJ, USA).
Study procedures
Patients were assigned to treatment groups (1:1 randomization) with computer-generated randomization codes. Target number of patients was 40 (20 in both treatment groups) and 6 additional patients were recruited to secure that representative samples were available from a sufficient number of patients (that is, a Per Protocol Study as mentioned in discussion). All patients (n ¼ 46) were followed for 18 months after the start of the study drug in spite of possible disease progression or intolerance to study medication (that is, intention to treat study).
In the dasatinib arm, the treatment was started with 100 mg once daily (QD) and in the imatinib arm with 400 mg QD (open-label study). In the case of toxicity, two possible dose reductions were permitted (70 and 50 mg for dasatinib and 300 and 200 mg for imatinib). In case of insufficient response, dose escalations were permitted, but dosing above 140 mg QD of dasatinib or 400 mg twice daily of imatinib was prohibited.
BM aspirate samples for cytogenetic analysis were taken at 0, 1, 3, 6, 12 and 18 months after the therapy start. BCR-ABL1 transcript levels were assessed by real-time quantitative PCR on peripheral blood samples at 0, 1, 3, 6, 12, 15 and 18 months. Results were reported using the international scale. Major molecular response (MMR) was determined according to the ELN criteria (BCR-ABL1p0.1% on international scale). 24 
Analysis of Ph þ cells in BM fractions
The assessment of primitive cell fractions was performed before and at 1, 3 and 6 months after the start of study drug. The mononuclear cell fraction was separated by Ficoll centrifugation (GE Healthcare Bio-Sciences AB, Uppsala, Sweden). CD34 þ cells were separated with paramagnetic beads (Miltenyi Biotech, Bergisch Gladbach, Germany). Pre-separated CD34 þ cells were stained with CD34 and CD38 antibodies (BD Biosciences, San Jose, CA, USA) after which the primitive cell fractions were sorted with flow cytometry (FACSAria, BD Biosciences) into two populations; the 80% with highest expression of CD38 (CD38 þ ) and the 5% with the lowest expression of CD38 (CD38 À ) (Figure 1 ).
The LSC fraction was defined as the fraction of cells with a Ph þ CD34 þ CD38 À phenotype from all stem cells (CD34 þ CD38 À ) analyzed. Similarly, the leukemia progenitor cell (LPC) fraction was defined as the fraction of cells with a Ph þ CD34 þ CD38 þ phenotype from all progenitor cells (CD34 þ CD38 þ ). Although no formal functional stem cell assays were performed, in the following, for simplicity, we refer to these populations as stem and progenitor cells, respectively.
After sorting, cytospin slides were made from different primitive cell fractions and additionally from unseparated whole BM samples from which red cells were lysed with FACS lysing buffer (BD Biosciences). The proportion of Ph þ cells was determined with FISH method using dual fusion dual color BCR-ABL1 probe (Vysis, Abbot, Downers Crove, IL, USA). The aim was to count at least 1000 cells from each cell fraction. The more detailed protocol has been described previously. 25 Before the trial start, quality control rounds were done between different stem cell laboratories (Helsinki, Lund, Oslo, and Stockholm University Hospitals). The same FISH sample slides were circulated among the laboratories and persons responsible for counting the FISH slides evaluated the proportion of positive cells in each slide. In addition, at two different time points, a BM aspirate sample was taken from a newly diagnosed CML patient and an aliquot of the sample was sent to each stem laboratory to assess reproducibility for the whole sorting and FISH procedure. The results were compared between various centers and an 490% concordance was achieved among different laboratories.
Statistical analysis
Statistical significance of differences in distributions, repeated measures and correlations were analyzed with two-sided non-parametric methods (Wilcoxon, Kruskal-Wallis, Spearman's rank tests), as appropriate. P-values o0.05 were considered statistically significant and calculated using PASW Statistics version 18.0 (SPSS Inc., Chicago, IL, USA).
RESULTS

Patients and feasibility of stem cell analysis
Between March 2009 and October 2010, 46 newly diagnosed patients with chronic phase CML (24 men and 22 women) were recruited at 10 academic centers in Finland, Norway and Sweden. The median age of the patients was 57 years (range 29-77 years). Other baseline characteristics are reported in Table 1 .
The median volume of BM aspirate received for stem cells analyses was 28, 37, 40 and 36 ml at diagnosis, 1, 3 and 6 months after therapy start, respectively. The median yield of BM mononuclear cells was 1000, 110, 93 and 79 Â 10 6 , respectively. Samples of sufficient quality from which the analysis of LSC fraction could be performed were obtained from 93% of patients at diagnosis, 83% at 1 month, 72% at 3 months and 89% at 6 months. The analysis of LPCs could be adequately accomplished in 93% of patients at diagnosis, in 91% at 1 month, 89% at 3 months and 93% at 6 months.
The proportion of LSCs at diagnosis correlates with biological variables At the time of diagnosis, the proportion of LSCs varied significantly between individual patients. Some patients had close Early therapy-related hematological toxicity is correlated with the LSC burden Patients were divided into two groups based on the median percentage of LSCs at the diagnosis ('high group', 479% of LSCs and 'low group', o79% of LSCs). Patients in the high group experienced more often hematological toxicity (grade 2 or higher) during the first 3 months of TKI therapy as compared with patients in the low group (55% vs 19%, respectively, P ¼ 0.024) (Figure 3a) . The difference was mostly due to neutropenia (45 vs 14%, P ¼ 0.025, Figure 3b ).
The LSC burden at diagnosis is a strong prognostic marker Overall, the treatment responses were very good in both treatment groups. At 12 months, all patients with representative samples available (dasatinib, n ¼ 21 and imatinib, n ¼ 21) were in complete cytogenetic remission. The molecular responses were substantially faster with dasatinib treatment and the median BCR-ABL1 transcript levels were significantly lower in dasatinib-treated patients at 3, 6, 12 and 18 months.
The (Supplementary Figure 1) . Similarly, the initial LSC burden correlated with BCR-ABL1 transcript levels at 3 (r ¼ 0.54, P ¼ 0.0005), 6 (r ¼ 0.42, P ¼ 0.0088) and 9 months (r ¼ 0.40, P ¼ 0.0123) (Figures 4a and b) . All patients who were not in MMR at 18 months, had 475% of Ph þ cells in the stem cell fraction at diagnosis (Figure 4c ). 
Impact of LSCs on therapy outcome in CML S Mustjoki et al
In the imatinib arm, only a few patients with high LSC burden at diagnosis achieved MMR at 12 months, whereas in the dasatinib arm most of the patients with a high LSC count were in MMR at 12 months (Figures 4d and e) .
TKI therapy eliminates the majority of Ph þ cells from stem and progenitor cell fractions During TKI therapy the proportion of Ph þ cells decreased rapidly in the stem and progenitor cell fractions. At 1 month, the median proportion of Ph þ cells was 14 and 56% in stem and progenitor cell fractions compared with 69% in whole BM (Po0.0001, n ¼ 38). At 3 months, the respective numbers were 0.2, 0.4 and 0.8% (P ¼ 0.087, n ¼ 33) and at 6 months 0, 0 and 0.1% (P ¼ 0.23, n ¼ 41) (Supplementary Figure 2) .
In the stem cell fraction, there was no statistically significant difference in the leukemia cell depletion between the treatment groups, as the proportion of LSCs at 1 month (dasatinib 11 vs imatinib 17%, P ¼ 0.91), 3 months (0.2 vs 0.3%, P ¼ 0.44) and 6 months (0 vs 0%, P ¼ 0.75) were similar between the groups ( Figure 5 ). In contrast, dasatinib appeared to deplete LPCs faster than imatinib, as observed at the 3 months time point (0.05 vs 0.68%, P ¼ 0.0318). Similar trend was also observed at 1 month (24 vs 69%, P ¼ 0.05) ( Figure 5 ).
When patients were divided into two groups based on LSC burden at diagnosis ('high and low', that is more or less than 79% Ph þ cells), we observed that in the high group, dasatinib was able to induce more rapid depletion of Ph þ cells both in the progenitor and stem cell fractions than imatinib (Figure 6a ). In the low group, there was no obvious difference between the Impact of LSCs on therapy outcome in CML S Mustjoki et al treatment arms (Figure 6b ). However, due to the small number of patients, no firm conclusions should be drawn.
DISCUSSION
To our knowledge, this is the first time in a clinical trial to prospectively assess the effect of targeted leukemia therapy on the hematopoietic stem and progenitor cell level. The results show that at diagnosis the proportion of LSCs in chronic phase CML patients is highly variable and is a strong prognostic marker correlating with other biological factors, such as white blood cell count, blast percentage and spleen size. In contrast to in vitro data, TKI therapy cleared most Ph þ cells from the stem cell compartment already within the first 6 months. To our surprise, the clearance of Ph þ cells in the primitive cell fractions was even faster than in the more mature cell fractions. Dasatinib induced a faster and deeper molecular response than imatinib, which was reflected at the progenitor cell level (LPCs) during the early course of treatment.
The proportion of leukemic cells varied considerably in the stem cell compartment at the study entry, although all patients were in chronic phase and not treated with TKIs before. Recently, residual normal hematopoietic stem cells have also been observed in CML patients' diagnostic marrow samples by two different flow cytometry-based methods. 26, 27 This differs from other hematopoietic stem cell diseases such as 5q-myelodysplastic syndrome in which it was recently shown that in all patients studied almost 100% of the hematopoietic stem cells are malignant. 28 We speculate that CML patients with a high stem cell disease burden at the time of diagnosis have a more advanced or biologically more complex disease. Accordingly, the LSC burden at diagnosis carried a strong prognostic value. Both patients who progressed during the study period (progression to blast crisis of an imatinib patient at 2 months and appearance of the V299L kinase domain mutation of a dasatinib patient at 9 months) had more than 90% of Ph þ leukemic cells in the stem cell compartment at diagnosis. Furthermore, all patients who did not achieve MMR at 18 months had 475% of Ph þ cells in the stem cell fraction at diagnosis. No similar predictive value was found when the leukemia burden was analyzed in whole BM or the LPCs.
In vitro experiments have suggested that TKIs are ineffective in eradicating quiescent malignant stem cells. 9, 10 In contrast, we show that Ph þ cells disappeared quickly from both the stem and progenitor cell fractions. At the 1-month time point, the bulk of BM was still heavily infiltrated with Ph þ leukemia cells, while in many patients the majority of cells in the progenitor and stem cell fractions were already Ph-negative. If one also considers that the BM cellularity, as judged from the number of mononuclear cells obtained at sampling, was reduced approximately 10-fold, the estimated absolute reduction of leukemia cells was even more impressive. The apparent discrepancy with the in vitro and in vivo results may have several explanations. The in vitro experiments, showing that especially quiescent LSCs are resistant to TKI therapy, are based on CD34 þ cells isolated at the time of diagnosis. At later time points, as assessed in our study, quiescent LSCs may relocate to the BM subendosteal niche by TKI-induced upregulation of the CXCR4 receptor and thus difficult to sample by routine BM aspiration techniques. 29, 30 In addition, as the initial difference in the median percentage of Ph þ cells in stem and progenitor fractions showed, LPCs may have a clear proliferative advantage over normal progenitor cells, whereas LSCs do not, and after the initiation of TKI therapy normal healthy hematopoietic stem cells rapidly overcome the residual LSCs. Hence, our findings show that the overwhelming majority of LSCs in vivo are sensitive to TKIs, but methodological limitations may still hamper our ability to identify the few residual quiescent LSCs, which are putatively responsible for relapse. This is in accordance with a recent publication showing that during nilotinib therapy Ph þ CD34 þ cells disappear quickly. 31 Large clinical trials with second-generation TKIs have shown that dasatinib and nilotinib induce more rapid and deeper responses in newly diagnosed CML patients as compared with imatinib. 5, 7, 32 Similarly, in the present study, dasatinib showed a clear benefit over imatinib with respect to molecular responses. The superior efficacy of dasatinib was observed also when patients with high LSC burden at diagnosis were considered. At 12 months, 100% of patients with a low LSC burden and 70% of patients with a high LSC burden at diagnosis were in MMR in the dasatinib arm. In the imatinib arm, the corresponding numbers were 44 and 40%. In addition to faster treatment responses, progression rates to accelerated and blast phase of CML is reduced with second-generation drugs. 5, 7, 32 The reason for this is unknown. Interestingly, our results indicate a faster clearance of Ph þ cells from the progenitor fraction in patients treated with dasatinib. This would fit well with earlier publications showing that granulocyte-macrophage progenitors are the candidate cells for leukemia progression. 33 In conclusion, both imatinib and dasatinib treatment depleted most of the malignant cells from primitive cell fractions. Dasatinib induced a faster reduction of primitive Ph þ cells by rapidly clearing the LPC compartment-a particularly transformationprone leukemic cell fraction. Patients with a high proportion of LSCs at diagnosis had worse cytogenetic and molecular responses and more hematological toxicity. LSC burden is a novel prognostic biomarker and may be very useful in detecting high-risk patients who would benefit from treatment intensification.
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